Epizyme, Inc. - Common Stock (NQ:EPZM)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 11, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Epizyme, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Epizyme: Q2 Earnings Insights ↗

August 09, 2022

Epizyme (NASDAQ:EPZM) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update

August 09, 2022

From Epizyme, Inc.

Via Business Wire

EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM

July 12, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM

June 27, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

Why Is Epizyme (EPZM) Stock Up 75% Today? ↗

June 27, 2022

EPZM stock is jumping higher today on news that Epizyme is being acquired by French pharmaceutical company Ipsen.

Via InvestorPlace

Why Epizyme Shares Are Soaring Today ↗

June 27, 2022

Epizyme Inc (NASDAQ: EPZM) shares are trading higher Monday after the company announced it entered into a definitive agreement to be acquired by Ipsen.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022 ↗

June 28, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies ↗

June 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027

June 28, 2022

Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent...

Via FinancialNewsMedia

Axsome Therapeutics (AXSM) Stock Soars on FDA Labeling Proposal ↗

June 27, 2022

Axsome Therapeutics (AXSM) stock is rising higher on Monday following an update from the FDA about product labeling for one of its drugs.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022 ↗

June 27, 2022

Upgrades

Via Benzinga

This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday ↗

June 28, 2022

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.

Via Benzinga

Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session ↗

June 27, 2022

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade.

Via Benzinga

EPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders

June 27, 2022

From Halper Sadeh LLP

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 27, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

June 27, 2022

Good morning, trader! We're starting off the week with an overview of the biggest pre-market stock movers for Monday morning!

Via InvestorPlace

Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why ↗

June 27, 2022

Ipsen SA (OTC: IPSEY) has

Via Benzinga

Epizyme + 20 Stocks Moving In Monday's Pre-Market Session ↗

June 27, 2022

Gainers Tenax Therapeutics, Inc. (NASDAQ: TENX) rose 90.1% to $0.59 in pre-market trading after dipping more than 46% on Friday.

Via Benzinga

Ipsen to acquire Epizyme, expanding its portfolio in oncology

June 27, 2022

From Epizyme, Inc.

Via Business Wire

76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More ↗

June 23, 2022

Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.

Via Benzinga

40 Stocks Moving In Wednesday's Mid-Day Session ↗

June 22, 2022

Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.

Via Benzinga

20 Stocks Moving in Tuesday's Pre-Market Session ↗

June 14, 2022

Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 48.5% to $2.57 in pre-market trading after the company reached an agreement with Phillip Morris for international electronic nicotine...

Via Benzinga

93 Biggest Movers From Yesterday ↗

June 14, 2022

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in...

Via Benzinga

91 Biggest Movers From Friday ↗

June 13, 2022

Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.

Via Benzinga

44 Stocks Moving In Friday's Mid-Day Session ↗

June 10, 2022

Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial.

Via Benzinga

25 Stocks Moving in Friday's Pre-Market Session ↗

June 10, 2022

Gainers Regis Corporation (NYSE: RGS) rose 74.4% to $0.9753 in pre-market trading. Regis partnered with salon technology provider Zenoti to support its 5,000+ locations.

Via Benzinga

Epizyme's Return On Capital Employed Insights ↗

June 09, 2022

Epizyme (NASDAQ:EPZM) brought in sales totaling $8.70 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 9.58%, resulting in a loss of $55.51 million.

Via Benzinga

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

June 02, 2022

From Epizyme, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

May 27, 2022

During Friday's session, 59 stocks hit new 52-week lows.

Via Benzinga

Epizyme To Participate in H.C. Wainwright Global Investment Conference

May 17, 2022

From Epizyme, Inc.

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.